Ovid Therapeutics (OVID) Retained Earnings (2016 - 2026)
Ovid Therapeutics (OVID) reported Retained Earnings of -$338.7 million for Q1 2026, down 720538.3% on a YoY basis from N/an in Q1 2025, and down 5.28% quarter-over-quarter from -$321.7 million in Q4 2025.
Ovid Therapeutics (OVID) Retained Earnings (2016 - 2026) Analysis & Trends
Ovid Therapeutics has reported Retained Earnings for 11 years, with the latest figure at -$338.7 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 720538.3% year-over-year to -$338.7 million; the trailing twelve-month figure through Mar 2026 stood at -$338.7 million (down 720538.3% YoY), and the FY2025 full-year result was -$321.7 million, down 5.72% from the prior year.
- Retained Earnings for Q1 2026 stood at -$338.7 million, down from -$321.7 million in the prior quarter.
- The five-year high for Retained Earnings was $1000.0 in Q4 2023, with the low at -$338.7 million in Q1 2026.
- Historically, Retained Earnings has averaged -$166.0 million across 5 years, with a median of -$238.9 million in 2023.
- Annual changes were most pronounced in 2023 — Retained Earnings surged 102.37% — and 2024, when it plunged 30430000.0%.
- Ovid Therapeutics' Retained Earnings stood at -$42187.0 in 2022, then surged by 102.37% to $1000.0 in 2023, then sank by 30430000.0% to -$304.3 million in 2024, then dropped by 5.72% to -$321.7 million in 2025, then retreated by 5.28% to -$338.7 million in 2026.
- The last three Retained Earnings figures came in at -$338.7 million (Q1 2026), -$321.7 million (Q4 2025), and -$331.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Ovid Therapeutics | 311.83 Mn | 156.31 Mn | - | -338.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -338.70 Mn |
| Dec 31, 2025 | -321.71 Mn |
| Sep 30, 2025 | -331.40 Mn |
| Jun 30, 2025 | -69,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -304.30 Mn |
| Sep 30, 2024 | -295.05 Mn |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | -289.60 Mn |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | -262.54 Mn |
| Jun 30, 2023 | -251.30 Mn |
| Mar 31, 2023 | -238.90 Mn |
| Dec 31, 2022 | -42,187.00 |
| Sep 30, 2022 | -82,792.00 |
| Jun 30, 2022 | -90,127.00 |
| Mar 31, 2022 | -187.50 Mn |
| Sep 30, 2021 | -145.36 Mn |
| Jun 30, 2021 | -133.97 Mn |
| Mar 31, 2021 | -118.18 Mn |